When it comes to headwinds testing big pharma’s strength, Bristol Myers Squibb Company is walking straight into the eye of the storm through the rest of this decade. BMS is trying to weather the loss of exclusivity for multiple blockbuster products as it launches new products into markets with strong competition and payer pushback while the US government ramps up efforts to control drug pricing. However, the company has numbers on its side, with 10 recent launches and 16 additional new drugs expected by 2030.
As BMS Braces For Major LOEs, It All Comes Down To Execution
16 NMEs Expected By The End Of This Decade
As Bristol Myers Squibb works through the Revlimid loss of exclusivity and prepares for the Eliquis and Opdivo LOEs, execution is key as it refills its pipeline with new launches and acquired assets.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.